» Articles » PMID: 24142406

Pyk2 and Src Mediate Signaling to CCL18-induced Breast Cancer Metastasis

Overview
Journal J Cell Biochem
Date 2013 Oct 22
PMID 24142406
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Pyk2 and Src phosphorylation is initiated by CCL18, which promotes breast cancer metastasis via its functional G protein-coupled receptor PITPNM3. However, the function of Pyk2 and Src in CCL18-induced breast cancer metastasis is poorly understood. Quantitative reverse-transcription polymerase chain reactions (qRT-PCRs), Western blot, boyden chamber assay, and adherence assay were performed to delineate the consequences of Pyk2/Src in CCL18-induced breast cancer cells. Co-immunoprecipitation and immunofluorescence were performed to analyze the interaction of proteins. Upon the binding of CCL18 to PITPNM3, Pyk2 translocates from the cytoplasm to the plasma membrane to form a stable complex with PITPNM3, subsequently activating Src kinase. Moreover, upon stimulation with CCL18, Pyk2 and Src become essential for integrin alpha5/beta1 clustering-dependent adherence, migration, and invasion. Pyk2 and Src are important in CCL18-induced breast cancer metastasis.

Citing Articles

Molecularly imprinted nanoparticles reveal regulatory scaffolding features in Pyk2 tyrosine kinase.

Zanela T, Zangiabadi M, Zhao Y, Underbakke E RSC Chem Biol. 2024; 5(5):447-453.

PMID: 38725907 PMC: 11078204. DOI: 10.1039/d3cb00228d.


Thrombin-Induced COX-2 Expression and PGE Synthesis in Human Tracheal Smooth Muscle Cells: Role of PKCδ/Pyk2-Dependent AP-1 Pathway Modulation.

Yang C, Lee I, Lin Y, Wu W, Hsiao L, Yang C Int J Mol Sci. 2023; 24(20).

PMID: 37894811 PMC: 10606820. DOI: 10.3390/ijms242015130.


Activated PyK2 and Its Associated Molecules Transduce Cellular Signaling from the Cancerous Milieu for Cancer Metastasis.

Lee D, Hong J Int J Mol Sci. 2022; 23(24).

PMID: 36555115 PMC: 9779422. DOI: 10.3390/ijms232415475.


CCL18 signaling from tumor-associated macrophages activates fibroblasts to adopt a chemoresistance-inducing phenotype.

Zeng W, Xiong L, Wu W, Li S, Liu J, Yang L Oncogene. 2022; 42(3):224-237.

PMID: 36418470 PMC: 9836934. DOI: 10.1038/s41388-022-02540-2.


Small Molecular Inhibitors Reverse Cancer Metastasis by Blockading Oncogenic PITPNM3.

Liu Z, Shi Y, Lv L, Chen J, Jiang W, Li J Adv Sci (Weinh). 2022; 9(35):e2204649.

PMID: 36285700 PMC: 9762305. DOI: 10.1002/advs.202204649.